Last $5.06 USD
Change Today -0.04 / -0.78%
Volume 14.2K
CPIX On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 09/23/14 All times are local (Market data is delayed by at least 15 minutes).

cumberland pharmaceuticals (CPIX) Snapshot

Open
$5.06
Previous Close
$5.10
Day High
$5.09
Day Low
$4.83
52 Week High
11/1/13 - $5.41
52 Week Low
05/8/14 - $4.20
Market Cap
88.9M
Average Volume 10 Days
19.3K
EPS TTM
$-0.06
Shares Outstanding
17.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CUMBERLAND PHARMACEUTICALS (CPIX)

cumberland pharmaceuticals (CPIX) Related Bloomberg News

View More Bloomberg News

cumberland pharmaceuticals (CPIX) Related Businessweek News

No Related Businessweek News Found

cumberland pharmaceuticals (CPIX) Details

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on acquiring, developing, and commercializing branded prescription products for the hospital acute care and gastroenterology markets in the United States. The company’s principal products comprise Acetadote, an intravenous formulation of N-acetylcysteine indicated for the treatment of acetaminophen poisoning; Caldolor, an intravenous formulation of ibuprofen for the treatment of pain and fever; and Kristalose, a prescription laxative administered orally for the treatment of constipation. Its products also include Omeclamox-Pak, a triple therapy combination medication for the treatment of Helicobacter pylori infection and duodenal ulcer disease; and Hepatoren injection, which is in Phase II clinical development for the treatment of hepatorenal syndrome. The company markets and sells its products through sales representatives and managers. Cumberland Pharmaceuticals Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.

96 Employees
Last Reported Date: 03/11/14
Founded in 1999

cumberland pharmaceuticals (CPIX) Top Compensated Officers

Founder, Chairman, Chief Executive Officer an...
Total Annual Compensation: $620.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $297.0K
Chief Development Officer and Senior Vice Pre...
Total Annual Compensation: $392.3K
Chief Commercial Officer, Senior Vice Preside...
Total Annual Compensation: $312.1K
Chief Compliance Officer and Vice President o...
Total Annual Compensation: $227.5K
Compensation as of Fiscal Year 2013.

cumberland pharmaceuticals (CPIX) Key Developments

Cumberland Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Cumberland Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported Revenue was $9.75 million against $7.081 million a year ago. Operating income was $1.22 million against loss of $1.14 million a year ago. Income before income taxes was $1.23 million against loss of $1.112 million a year ago. Net income attributable to common shareholders was $722.57 million against loss of $639.02 million a year ago. Diluted earnings per share were $0.04 against loss of $0.03 a year ago. For the six months, the company reported Revenue was $17.84 million against $17.339 million a year ago. Operating income was $1.62 million against $0.185 million a year ago. Income before income taxes was $1.696 million against $0.288 million a year ago. Net income attributable to common shareholders was $1.009 million against $0.216 million a year ago. Diluted earnings per share were $0.06 against $0.01 a year ago. Net cash provided by operating activities was $1.82 million against $1.79 million a year ago. Additions to property and equipment were $0.048 million against $0.069 million a year ago. Additions to intangible assets were $0.732 million against $1.83 million a year ago.

Cumberland Pharmaceuticals Seeks Acquisitions

Cumberland Pharmaceuticals, Inc. (NasdaqGS:CPIX) will consider acquisitions. Cumberland has entered into a new three year line of credit with SunTrust Bank providing up to $20 million in debt financing availability to support Cumberland's growth and acquisition initiative.

Cumberland Pharmaceuticals, Inc. to Report Q2, 2014 Results on Aug 05, 2014

Cumberland Pharmaceuticals, Inc. announced that they will report Q2, 2014 results at 5:00 PM, Eastern Standard Time on Aug 05, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CPIX:US $5.06 USD -0.04

CPIX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cubist Pharmaceuticals Inc $65.58 USD -0.63
Durect Corp $1.51 USD -0.01
Ironwood Pharmaceuticals Inc $12.19 USD -0.08
Pacira Pharmaceuticals Inc/DE $101.20 USD -2.93
Sucampo Pharmaceuticals Inc $6.55 USD -0.07
View Industry Companies
 

Industry Analysis

CPIX

Industry Average

Valuation CPIX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.8x
Price/Book 1.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CUMBERLAND PHARMACEUTICALS, please visit www.cumberlandpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.